Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer

The present treatments for lung cancer include surgical resection, radiation, chemotherapy, targeted therapy, and immunotherapy. Despite advances in therapies, the prognosis of lung cancer has not been substantially improved in recent years. Chimeric antigen receptor (CAR)-T cell immunotherapy has attracted growing interest in the treatment of various malignancies. Despite CAR-T cell therapy emerging as a novel potential therapeutic option with promising results in refractory and relapsed leukemia, many challenges limit its therapeutic efficacy in solid tumors including lung cancer. In this landscape, studies have identified several obstacles to the effective use of CAR-T cell therapy including antigen heterogeneity, the immunosuppressive tumor microenvironment, and tumor penetration by CAR-T cells. Here, we review CAR-T cell design; present the results of CAR-T cell therapies in preclinical and clinical studies in lung cancer; describe existing challenges and toxicities; and discuss strategies to improve therapeutic efficacy of CAR-T cells.

• Publication year

  2022

• Venue

  Frontiers in Immunology

• Publication date

  2022-06-02

• Fields of study

  Medicine

• Identifiers
  DOI 10.3389/fimmu.2022.903562PMID 35720364PMCID 9201083
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Reversible Chemogenetic Switch for Chimeric Antigen Receptor T Cells

  2022cited by this paper
• Remodeling metabolic fitness: Strategies for improving the efficacy of chimeric antigen receptor T cell therapy.

  2022cited by this paper
• Chimeric CTLA4-CD28-CD3z T Cells Potentiate Antitumor Activity Against CD80/CD86–Positive B Cell Malignancies

  2021cited by this paper
• Switchable CAR-T Cells Outperformed Traditional Antibody-Redirected Therapeutics Targeting Breast Cancers.

  2021cited by this paper
• Prognostic Impact of PD-L1 Expression in pN1 NSCLC: A Retrospective Single-Center Analysis

  2021cited by this paper
• T cells armed with the C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours

  2021cited by this paper
• Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors

  2021cited by this paper
• Targeted therapy of non-small cell lung cancer.

  2021cited by this paper
• Optimization of CAR-T Cell-Based Therapies Using Small-Molecule-Based Safety Switches.

  2021cited by this paper
• A Recurring Chemogenetic Switch for Chimeric Antigen Receptor T Cells

  2021cited by this paper
• Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity.

  2021cited by this paper
• Chimeric Antigen Receptor T-Cell Therapy in Lung Cancer: Potential and Challenges

  2021cited by this paper
• Single-Cell Analysis of Target Antigens of CAR-T Reveals a Potential Landscape of “On-Target, Off-Tumor Toxicity”

  2021cited by this paper
• Faculty Opinions recommendation of T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours.

  2021cited by this paper
• Cancer Statistics, 2021

  2021cited by this paper
• Chemically programmable and switchable CAR-T therapy.

  2020cited by this paper
• Targeting glutamine metabolism enhances tumor specific immunity by modulating suppressive myeloid cells.

  2020cited by this paper
• Tumor Microenvironment, Metabolism, and Immunotherapy.

  2020cited by this paper
• Interleukin-23 engineering improves CAR T cell function in solid tumors

  2020cited by this paper
• Bidirectional signals of PD-L1 in T cells that fraternize with cancer cells

  2020cited by this paper
• CAR T Cells Redirected to CD44v6 Control Tumor Growth in Lung and Ovary Adenocarcinoma Bearing Mice

  2020cited by this paper
• Immune Modulation in Lung Cancer: Current Concepts and Future Strategies

  2020cited by this paper
• Fluorescence In Situ Hybridization

  2020cited by this paper
• Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives

  2020cited by this paper
• Breaking Bottlenecks for the TCR Therapy of Cancer

  2020cited by this paper
• Targeting PD-L1 in non-small cell lung cancer using CAR T cells

  2020cited by this paper
• Spatial Density and Distribution of Tumor-Associated Macrophages Predict Survival in Non–Small Cell Lung Carcinoma

  2020cited by this paper
• Metabolic engineering against the arginine microenvironment enhances CAR-T cell proliferation and therapeutic activity.

  2020cited by this paper
• Chimeric antigen receptor T cells targeting PD-L1 suppress tumor growth

  2020cited by this paper
• CAR-T cell therapy for lung cancer: a promising but challenging future

  2020cited by this paper
• LunX-CAR T Cells as a Targeted Therapy for Non-Small Cell Lung Cancer

  2020cited by this paper
• Isocitrate Dehydrogenase Mutations in Glioma: From Basic Discovery to Therapeutics Development

  2019cited by this paper
• Solid Tumors Challenges and New Insights of CAR T Cell Engineering

  2019cited by this paper
• ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.

  2019cited by this paper
• Determinants of response and resistance to CAR T cell therapy.

  2019cited by this paper
• Armored Inducible Expression of IL-12 Enhances Antitumor Activity of Glypican-3–Targeted Chimeric Antigen Receptor–Engineered T Cells in Hepatocellular Carcinoma

  2019cited by this paper
• Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy

  2019cited by this paper
• Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion

  2019cited by this paper
• Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors.

  2019cited by this paper
• Engineering strategies to overcome the current roadblocks in CAR T cell therapy

  2019cited by this paper
• Nr4a transcription factors limit CAR T cell function in solid tumors

  2019cited by this paper
• Target selection of CAR T cell therapy in accordance with the TME for solid tumors.

  2019cited by this paper
• Combining the best of two worlds: highly flexible chimeric antigen receptor adaptor molecules (CAR-adaptors) for the recruitment of chimeric antigen receptor T cells

  2019cited by this paper
• Logic-Gated ROR1 Chimeric Antigen Receptor Expression Rescues T Cell-Mediated Toxicity to Normal Tissues and Enables Selective Tumor Targeting.

  2019cited by this paper
• Cancer-cell-secreted CXCL11 promoted CD8+ T cells infiltration through docetaxel-induced-release of HMGB1 in NSCLC

  2019cited by this paper
• Characteristics and Outcomes of Patients With Metastatic KRAS‐Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience

  2019cited by this paper
• Chemokines Modulate Immune Surveillance in Tumorigenesis, Metastasis, and Response to Immunotherapy

  2019cited by this paper
• MAGE-A1 in lung adenocarcinoma as a promising target of chimeric antigen receptor T cells

  2019cited by this paper
• Engineered T Cell Therapy for Cancer in the Clinic

  2019cited by this paper
• ROR1-CAR T-cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models.

  2019cited by this paper
• Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades

  2019cited by this paper
• CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment

  2019cited by this paper
• CAR T-cell Therapy for Solid Tumors?

  2018cited by this paper
• Mesothelin-targeted second generation CAR-T cells inhibit growth of mesothelin-expressing tumors in vivo

  2018cited by this paper
• Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

  2018cited by this paper
• Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors

  2018cited by this paper
• T cell senescence and CAR-T cell exhaustion in hematological malignancies

  2018cited by this paper
• Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries.

  2018cited by this paper
• CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade

  2018cited by this paper
• CURRENT STATUS AND FUTURE PERSPECTIVES

  2018cited by this paper
• Antitumor activity of EGFR-specific CAR T cells against non-small-cell lung cancer cells in vitro and in mice

  2018cited by this paper
• Chimeric Antigen Receptor (CAR) T‐Cell Therapy for Thoracic Malignancies

  2018cited by this paper
• The effects of 2-hydroxyglutarate on the tumorigenesis of gliomas

  2018cited by this paper
• Teaching an old dog new tricks: next-generation CAR T cells

  2018cited by this paper
• Combination Therapy of Radiotherapy and Anti‐PD‐1/PD‐L1 Treatment in Non–Small‐cell Lung Cancer: A Mini‐review

  2018cited by this paper
• Tumor Antigen Escape from CAR T-cell Therapy.

  2018cited by this paper
• Targeting the tumour stroma to improve cancer therapy

  2018cited by this paper
• Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses.

  2018cited by this paper
• Cytokine release syndrome

  2018cited by this paper
• Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo

  2018cited by this paper
• Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia.

  2018cited by this paper
• Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence

  2017cited by this paper
• Chimeric Antigen Receptor-Modified T Cells Redirected to EphA2 for the Immunotherapy of Non-Small Cell Lung Cancer

  2017cited by this paper
• Migrating into the Tumor: a Roadmap for T Cells.

  2017cited by this paper
• mSA2 affinity-enhanced biotin-binding CAR T cells for universal tumor targeting

  2017cited by this paper
• CAR T Cells Releasing IL-18 Convert to T-Bethigh FoxO1low Effectors that Exhibit Augmented Activity against Advanced Solid Tumors.

  2017cited by this paper
• Progress and prospects of early detection in lung cancer

  2017cited by this paper
• CAR T-cell therapy for lung cancer and malignant pleural mesothelioma.

  2017cited by this paper
• Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells.

  2017cited by this paper
• Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants

  2017cited by this paper
• PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells

  2017influential reference
• CAR T Cell Therapy for Solid Tumors.

  2017cited by this paper
• Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells.

  2017influential reference
• Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma

  2017influential reference
• Mechanisms regulating T-cell infiltration and activity in solid tumors.

  2017cited by this paper
• Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells

  2017cited by this paper
• Tumour heterogeneity and resistance to cancer therapies

  2017cited by this paper
• Coexpressed Catalase Protects Chimeric Antigen Receptor–Redirected T Cells as well as Bystander Cells from Oxidative Stress–Induced Loss of Antitumor Activity

  2016cited by this paper
• Analysis of ROR1 Protein Expression in Human Cancer and Normal Tissues

  2016cited by this paper
• CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells

  2016cited by this paper
• Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells

  2016cited by this paper
• GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade.

  2016cited by this paper
• Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy

  2016cited by this paper
• Toxicity and management in CAR T-cell therapy

  2016cited by this paper
• Tailored chemokine receptor modification improves homing of adoptive therapy T cells in a spontaneous tumor model

  2016cited by this paper
• L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity

  2016cited by this paper
• Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors.

  2016cited by this paper
• Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review

  2016cited by this paper
• CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date.

  2016cited by this paper
• Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy.

  2016cited by this paper

• Current status and perspective of off-the-shelf CAR-T cells in cancer immunotherapy.

  2026cites this paper
• Next-generation immune cell therapies for lung cancer: advances in CAR-T, NK, and TIL strategies

  2026cites this paper
• Dextran-based T-cell expansion nanoparticles for manufacturing CAR T cells with augmented efficacy

  2026cites this paper
• Novel Strategies for the Treatment of Lung Cancer: An In-depth Analysis of the Use of Immunotherapy, Precision Medicine, and Artificial Intelligence to Improve Prognoses.

  2025cites this paper
• Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition

  2025cites this paper
• DNA Nanostructures‐Based In Situ Cancer Vaccines: Mechanisms and Applications

  2025cites this paper
• Tumor-infiltrating B cells in non-small cell lung cancer: current insights and future directions

  2025cites this paper
• CD8+ T cell-based immunotherapy: Promising frontier in human diseases.

  2025cites this paper
• In Vitro Study of Cancer Stem Cells and Reprogrammed CD3+CD8+ T Cells: the Search for Personalized Diagnostics and Targeted Treatment of Small Cell Lung Cancer (Experience of a Pilot Study)

  2025cites this paper
• Role of CAR-T cell K+ channels in tumor infiltration and elimination.

  2025cites this paper
• Adoptive cell therapy for cancer: combination strategies and biomarkers

  2025cites this paper
• SLAMF7: A Potential Target for CAR T-Cell Therapy in Multiple Myeloma

  2025cites this paper
• mRNA-engineered T lymphocytes secreting bispecific T cell engagers with therapeutic potential in solid tumors

  2025cites this paper
• Targeted drug conjugates and molecular mechanisms in overcoming lung cancer drug resistance

  2025cites this paper
• GPCRs in CAR-T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy.

  2025cites this paper
• A new vision of the efficacy of both CAR-NK and CAR-T cells in treating cancers and autoimmune diseases

  2024cites this paper
• The synergistic immunotherapeutic impact of engineered CAR-T cells with PD-1 blockade in lymphomas and solid tumors: a systematic review

  2024cites this paper
• [Optimizing efficacy and security of CAR-T cells, and immune monitoring].

  2024cites this paper
• Revolutionizing Cancer Treatments through Stem Cell-Derived CAR T Cells for Immunotherapy: Opening New Horizons for the Future of Oncology

  2024cites this paper
• Focusing on exosomes to overcome the existing bottlenecks of CAR-T cell therapy

  2024cites this paper
• Emerging advances in nano-biomaterial assisted amyloid beta chimeric antigen receptor macrophages (CAR-M) therapy: reducing plaque burden in Alzheimer’s disease

  2024cites this paper
• Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice

  2024cites this paper
• Editorial: Emerging learnings in cell therapy: novel binding domains, universal CAR-T cells, and more.

  2024cites this paper
• In Vitro Studies May Be Useful in Donor Selection and Evaluating the Effectiveness of CD8+ T-Cell Reprogramming: Experience of a Pilot Study

  2023cites this paper
• Editorial: Systemic immune dysregulation in malignant disease: Insights, monitoring and therapeutic exploitation

  2023cites this paper
• Cellular Therapy for Lung Cancer: Focusing on Chimeric Antigen Receptor T (CAR T) Cells and Tumor-Infiltrating Lymphocyte (TIL) Therapy

  2023cites this paper
• A promising future in cancer immunotherapy: Oncolytic viruses.

  2023cites this paper
• Cell Therapy with Human Reprogrammed CD8+ T-Cells Has Antimetastatic Effects on Lewis Lung Carcinoma in C57BL/6 Mice

  2022cites this paper
• Drug resistance mechanisms and progress in the treatment of EGFR-mutated lung adenocarcinoma

  2022cites this paper
• World Journal of Clinical Oncology

  year unknowninfluential citation